Compare FSV & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | PCVX |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.0B |
| IPO Year | 2015 | 2020 |
| Metric | FSV | PCVX |
|---|---|---|
| Price | $139.94 | $53.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $208.25 | $88.25 |
| AVG Volume (30 Days) | 213.5K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $49.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $119.41 | $29.10 |
| 52 Week High | $205.99 | $65.00 |
| Indicator | FSV | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 60.67 |
| Support Level | $133.42 | $52.04 |
| Resistance Level | $157.74 | $56.04 |
| Average True Range (ATR) | 4.59 | 2.37 |
| MACD | -0.36 | 0.94 |
| Stochastic Oscillator | 65.00 | 74.71 |
FirstService Corp is engaged in outsourcing property services. The company operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertaPro Painters, Floor Coverings International, and Pillar to Post Home Inspectors. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.